References
- Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J. Neurol. Neurosurg. Psychiatry60(2), 197–199 (1996).
- Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci.143(1–2), 1–13 (1996).
- Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke37(2), 577–617 (2006).
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet342(8882), 1255–1262 (1993).
- Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention in Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology53(6), 1319–1327 (1999).
- Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet367(9523), 1665–1673 (2006).
- Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol.6(2), 115–124 (2007).
- Halkes PHA, Gray LJ, Bath PMW et al. Dipyridamole plus aspirin versus aspirin alone in the secondary prevention after TIA or stroke: a meta-analysis by risk. J. Neurol. Neurosurg. Psychiatry (2008) (Epub ahead of print).
- Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke39(4), 1358–1363 (2008).
- De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst. Rev. (2), CD001820 (2006).
- Fisher CM. Capsular infarcts: the underlying vascular lesions. Arch. Neurol.36(2), 65–73 (1979).
- van Zagten M, Boiten J, Kessels F, Lodder J. Significant progression of white matter lesions and small deep (lacunar) infarcts in patients with stroke. Arch. Neurol.53(7), 650–655 (1996).
- De Schryver EL. Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. Stroke34(10), 2339–2342 (2003).
- Adams RJ, Albers G, Alberts MJ et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke39(5), 1647–1652 (2008).
- Lammie G. Pathology of lacunar infarction. In: Subcortical Stroke. Donnan G, Norrving B, Bamford J, Bogousslavsky J (Eds). Oxford University Press, Oxford, UK, 37–46 (2002).
- de Jong G, Kessels F, Lodder J. Two types of lacunar infarcts: further arguments from a study on prognosis. Stroke33(8), 2072–2076 (2002).
- Staals J, van Raak L, Hilton A, Lodder J. Differences in long-term survival in two lacunar stroke types: a 15-year follow-up study in 782 cerebral infarct patients. Cerebrovasc. Dis.25(1–2), 26–31 (2007).